a; Björn Fagerberg, MDb; Björn Andersson, PhD, MDb; Göran Matejka, PhD, MDb; Bengt Persson, PhD, MDb">
Advertisement
Journal Home
Search for

Volume 32, Issue 1, Pages 3-9 (January 2003)


View previous. 2 of 13 View next.

Can treatment with angiotensin-converting enzyme inhibitors in elderly patients with moderate to severe chronic heart failure be improved by a nurse-monitored structured care program? A randomized controlled trial☆☆

Inger Ekman, PhD, RNa, Björn Fagerberg, MDb, Björn Andersson, PhD, MDb, Göran Matejka, PhD, MDb, Bengt Persson, PhD, MDb

Abstract 

Objective: The purpose of this study was to examine whether a nurse-monitored structured care program resulted in a more effective use of angiotensin-converting enzyme (ACE) inhibitors in elderly patients compared with standard care in patients with chronic heart failure (CHF). Methods: Hospitalized patients were screened to identify individuals with CHF, age more than 65 years, New York Heart Association classification III to IV, and no contraindications to ACE inhibitor treatment. One hundred forty-five patients were randomized to a nurse-monitored structured care program that included uptitration of enalapril to a target dose of 10 mg twice a day or to standard care. Six-month follow-up data were collected. Results: The mean age of the randomized patients was 81 years. Although the proportion of patients treated with an ACE inhibitor did not differ between structured care (70%) and standard care (64%), the number of patients with the target ACE inhibitor dose was significantly higher in the structured care group (26% versus 11% in the standard care group; P < .018). Treatment had to be discontinued in 26% of the patients because of adverse effects. Conclusion: The patients in this study were older than in previous intervention studies and had considerable comorbidity and reduced tolerance for ACE inhibitors. ACE inhibitor treatment was underused but improved with the structured care program, although achieved treatment levels were below those in the large intervention trials in patients with CHF. (Heart Lung® 2003;32:3-9.)

Göteborg, Sweden

From The Sahlgrenska Academy at Göteborg University, aFaculty of Health and Caring Sciences, Institute of Nursing, and the bFaculty of Medicine, Institute of Medicine, Sahlgrenska University Hospital/Sahlgrenska, Göteborg, Sweden

 Supported by grants from the Swedish Medical Research Council, Hjärt-och lungsjukas riksförbund, and Merck, Sharp & Dohme.

☆☆ Reprint requests: Inger Ekman, The Sahlgrenska Academy at Göteborg University, Faculty of Health and Caring Sciences, Institute of Nursing, Box 457 405 30, Göteborg, Sweden.

 0147-9563/2003/$30.00 + 0

PII: S0147-9563(02)70205-7

doi:10.1067/mhl.2003.5


View previous. 2 of 13 View next.

Advertisement